Nxera Pharma to Receive $3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US $3 million to Nxera pursuant to its research collaboration with Centessa.